BEY-2153

N/A

Report date: 2025/03/22 20:00:05

NME

Base Information

Drug NameBEY-2153

Drug Alias NameBEY-2153

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAnti-APPAnti-TAU

TargetsBeta amyloid A4 proteinMicrotubule-associated protein tau

Therapy Area/IndicationsAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBeyondbio Inc

China Registration ClassN/A

Active CompaniesBeyondbio Inc

Inactive CompaniesN/A

Active IndicationsAlzheimer Disease

Inactive IndicationsN/A

ATC CodeN/A